Amneal Pharmaceuticals, Inc. - 10-Q Filing
Amneal Pharmaceuticals filed its Q1 2026 10-Q report with the SEC, disclosing financial results for January to March 2026. The company reported revenue of $795 million and a net loss per share of ($0.34), compared to revenue of $805 million and earnings per share (EPS) of $0.19 in Q1 2025.
Tickers: $AMRX